This study aimed to characterize the in vivo biodistribution of [<sup>52</sup>Mn]Mn-BPPA-bevacizumab, and to compare the tumor-to-background ratios of [<sup>52</sup>Mn]Mn-BPPA-bevacizumab with the previously published values of [<sup>52</sup>Mn]Mn-DOTAGA-bevacizumab in VEGF-A-expressing cervix carcinoma. The gene discussed is VEGFA; the disease is cervical carcinoma.